Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Avalo Therapeutics, Inc. (AVTX : NSDQ)

• Company Description    Avalo Therapeutics Inc. is a clinical-stage precision medicine company which discovers, develops and commercializes targeted therapeutics for patients with significant unmet clinical need in immunology, immuno-oncology and rare genetic diseases. Avalo Therapeutics Inc., formerly known as Cerecor, is based in WAYNE, Pa. Number of Employees: 23

• Price / Volume Information    Yesterday's Closing Price: $15.05 Daily Weekly Monthly 20 Day Moving Average: 376,204 shares Shares Outstanding: 13.15 (millions) Market Capitalization: $197.94 (millions) Beta: 0.94 52 Week High: $19.41 52 Week Low: $3.39 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 7.89% 5.06% 12 Week 66.85% 59.93% Year To Date 102.56% 77.06%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1500 Liberty Ridge Drive Suite 321 - Wayne,PA 19087 USA ph: 410-522-8707 fax: - ir@avalotx.com http://www.avalotx.com

• General Corporate Information    Officers Garry Neil - President and Chief Executive Officer; Chairman Christopher Sullivan - Chief Financial Officer June Almenoff - Director Mitchell Chan - Director Jonathan Goldman - Director Peer Information Avalo Therapeutics, Inc. (GSAC) Avalo Therapeutics, Inc. (CASI) Avalo Therapeutics, Inc. (ALCD.) Avalo Therapeutics, Inc. (OMNN) Avalo Therapeutics, Inc. (CGPI.) Avalo Therapeutics, Inc. (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 05338F306 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/19/26 Share - Related Items Shares Outstanding: 13.15 Most Recent Split Date: 12.00 (0.00:1) Beta: 0.94 Market Capitalization: $197.94 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-1.55 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-6.76 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/19/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.16 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 22.61% vs. Previous Quarter: -14.06% Sales Growth vs. Year Ago Period: -66.32% vs. Previous Quarter: -22.89% ROE 09/30/25 - -88.43 06/30/25 - -48.48 03/31/25 - 111.00 ROA 09/30/25 - -73.86 06/30/25 - -35.94 03/31/25 - 58.88 Current Ratio 09/30/25 - 14.28 06/30/25 - 12.44 03/31/25 - 22.61 Quick Ratio 09/30/25 - 14.28 06/30/25 - 12.44 03/31/25 - 22.61 Operating Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Net Margin 09/30/25 - - 06/30/25 - - 03/31/25 - - Pre-Tax Margin 09/30/25 - -51,942.19 06/30/25 - -10,451.70 03/31/25 - 16,582.08 Book Value 09/30/25 - 6.96 06/30/25 - 9.66 03/31/25 - 11.32 Inventory Turnover 09/30/25 - - 06/30/25 - - 03/31/25 - - Debt-to-Equity 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00 Debt-to-Capital 09/30/25 - 0.00 06/30/25 - 0.00 03/31/25 - 0.00

Powered by Zacks Investment Research ©